Regulus Therapeutics Inc (RGLS)

1.40
NASDAQ : Health Care
Prev Close 1.50
Day Low/High 1.40 / 1.55
52 Wk Low/High 0.94 / 6.68
Avg Volume 1.16M
Exchange NASDAQ
Shares Outstanding 52.93M
Market Cap 79.40M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. Lead Plaintiff Deadline Of April 3, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. Lead Plaintiff Deadline Of April 3, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc.

RGLS INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

RGLS INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. -Lead Plaintiff Deadline Of April 3, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. -Lead Plaintiff Deadline Of April 3, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

RGLS SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

RGLS SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc.

Regulus To Release Fourth Quarter And Full Year 2016 Financial Results On March 2, 2017

Regulus To Release Fourth Quarter And Full Year 2016 Financial Results On March 2, 2017

Conference Call and Webcast to Follow

Regulus Announces Publication In Nature Communications Identifying MiR-17 As A Promising Drug Target For ADPKD

Regulus Announces Publication In Nature Communications Identifying MiR-17 As A Promising Drug Target For ADPKD

Published results from preclinical studies show inhibition of miR-17 increased survival and reduced disease burden in mice

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc.

Regulus Announces Continuation Of RG-101 Clinical Hold

Regulus Announces Continuation Of RG-101 Clinical Hold

FDA requests longer-term follow-up data from ongoing studies

Regulus To Release Third Quarter Financial Results On November 1, 2016

Regulus To Release Third Quarter Financial Results On November 1, 2016

Conference Call and Webcast to Follow

Regulus Provides Update On Clinical Hold Of RG-101

Regulus Provides Update On Clinical Hold Of RG-101

On Track to Deliver Follow-up Results from On-going RG-101 Studies

Regulus To Release Second Quarter Financial Results On August 2, 2016

Regulus To Release Second Quarter Financial Results On August 2, 2016

Conference Call and Webcast to Follow